ABOS Stock Summary and Trading Ideas (Acumen Pharmaceuticals | NASDAQ:ABOS)

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.

As of December 24, 2025, ABOS stock price declined to $2.16 with 92,766 million shares trading.

ABOS has a beta of 2.08, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.23 to the broad based SPY ETF.

ABOS has a market cap of $130.84 million. This is considered a Micro Cap stock.

In the last 3 years, ABOS traded as high as $11.31 and as low as $.86.

The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, IWC, DFAC, AVSC.

ABOS has outperformed the market in the last year with a price return of +22.0% while the SPY ETF gained +17.3%. ABOS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +75.6% and +10.8%, respectively, while the SPY returned +4.4% and +1.4%, respectively.

ABOS support price is $2.05 and resistance is $2.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.